Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Congenital FVII Deficiency - Registry for All Treated Patients

This study is conducted in Japan. The aim of this observational study is to evaluate the long-term safety and efficacy of activated recombinant human factor VII (NovoSeven®) in subjects with congenital FVII deficiency.

Inclusion Criteria:

• Congenital FVII deficiency
• Never been treated with NovoSeven® before
• Patients already in treatment with NovoSeven®

Exclusion Criteria:

• History of hypersensitivity to any of the components in NovoSeven®